Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC)

• Status: Unknown status
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Squamous Cell Carcinoma (SCC) is one of the most common malignancies in caucasian population. The effect of the immune system on the development of skin tumors has been demonstrated in transplant patients taking immunosuppressive agents (65 fold risk increase). It has been reported that activation of EGFR and RAS signaling pathways play an important role in disease progression maybe through downregulation of the immune system.

The investigators want to treat unresectable SCC patients with an antibody against EGFR (Vectibix®, panitumumab). This antibody induces tumor regression in metastatic colorectal cancer and has been approved as single agent for this indication.

The investigators want to measure the response rate but also analyze the modification of expression profile of some key proteins involved or supposed to be involved in the signaling pathways of EGFR and in the regulation of the immune system. Chemokines such as CCL27 have been shown to play a critical role in the skin-associated immune response by regulating T cell homing. Pivarcsi et al have reported that downregulation of CCL27 is mediated by activation of EGFR/RAS/MAPK signaling pathways.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
• Collaborators: Cliniques Saint-Pierre Ottignies, Dr Lionel Duck; Cliniques Universitaires UCL de Mont-Godinne, Dr Joseph Kerger
• Treatments: Antibodies, Monoclonal; Panitumumab

Criteria

Inclusion criteria

• Patient with histologically confirmed diagnosis of SCC.

• Patient must not be candidate to direct curative surgery.

• Tumor evaluation by photography with a ruler and CT-scan, MRI or PET-scan must be performed before enrollment.

• Age ≥ 18 years.

• Karnofsky Performance status (KPS) ≥70.

• Normal laboratory values:

• Platelet count ≥100x103/μL

• Leucocyte count ≥ 3x103/μL

• Hemoglobin ≥ 9 g/dL

• ASAT and ALAT ≤ 2.5xUNL

• Serum creatinine ≤1.5xUNL

• Total bilirubin ≤ 1.5xUNL

• Magnesium ≥ Lower Normal Limit (LLN)

• Calcium ≥ Lower Normal Limit (LLN)

• Patient should agree to perform biopsies and blood collections for translational research.

• Signed informed consent from the patient or legal representative must be obtained.

Exclusion criteria

• Clinically significant cardiovascular disease (including cardiac insufficiency NYHA grade III and IV, unstable angina, arrythmia, myocardial infarction, symptomatic congestive heart failure)in the past 12 months before enrollment.

• History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan.

• No prior chemotherapy.

• Prior anti-EGFR therapy.

• Radiation within four weeks prior to trial entry.

• Subject pregnant or breastfeeding, or planning to become pregnant within 6 months after the end of treatment.

• Subject (male or female) not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months after the end of treatment.

• The patient has (or has had) previous or concomitant malignancies at other sites within last 5years, except effectively treated malignancy that is considered by the investigator highly likely to have been cured.